TheBrief.Health
Adagio Medical’s FDA submission for its ultra-low temperature ventricular ablation system could expand treatment options for drug-refractory ventricular tachycardia, offering deeper lesion creation, fewer ICD shocks, reduced antiarrhythmic dependence, and improved procedural outcomes.
518 jaksot
Kommentit
0Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity TheBrief.Health-yhteisöön!